NCT06973382Not yet recruiting
Effects of Pulmonary Rehabilitation on Quality of Life and Health in Pulmonary Arterial Hypertension Patients
Intervention Study of a Comprehensive Pulmonary Rehabilitation Program on Quality of Life and Prognosis in Patients With Pulmonary Arterial Hypertension
Source: ClinicalTrials.gov · Last updated 15 May 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Pulmonary hypertension (PH) is a major global health concern, affecting approximately 1% of the world's population. With global aging and increased life expectancy, its incidence continues to rise. PH is a progressive and disabling disease, with studies showing its progression correlates with worsening symptoms and increased mortality. Even with targeted medications, the prognosis remains poor across PH subtypes, with PAH patients showing only a 49% 7-year survival rate. The 2022 ESC/ERS guidelines emphasize that PH management requires a comprehensive, multidisciplinary approach. Beyond pharmacological and surgical treatments, rehabilitation has demonstrated benefits in improving exercise capacity, quality of life, functional class, and peak oxygen consumption. However, research on specific and effective comprehensive pulmonary rehabilitation programs remains lacking.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 84 (estimated)
- First submitted
- 14 May 2025
- Start date
- 20 May 2025
- Primary completion date
- 31 Oct 2027
- Lead sponsor
- Beijing Chao Yang Hospital
- NCT number
- NCT06973382
What you commit to
- Study type: Interventional
- Planned participants: 84
- From 20 May 2025 to the primary completion date, 31 Oct 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of non-adherence making protocol completion unlikely
Other
- Unable to perform pulmonary rehabilitation exercises due to disability or congenital malformations
- Cardiopulmonary Testing Contraindications:
- Medically unfit to complete CPET (cardiopulmonary exercise testing) after evaluation
- Poor Compliance:
- Life Expectancy:
- Prognosis ≤1 year
- \-
Who the study is looking for
- Right heart catheterization-confirmed pulmonary hypertension
- Meets 2022 ESC/ERS Guidelines diagnostic criteria for:
- Group 1 (PAH) or
- Group 4 (CTEPH/other pulmonary artery obstructions)
- Stabilized Treatment Status:
- Group 1 (PAH): Received ≥3 months of targeted drug therapy
- Group 4 (CTEPH): Completed ≥6 sessions of BPA\* or reached therapeutic endpoint
- Functional Capacity:
- WHO Functional Class I-III
- Age: ≥18 years
- Consent: Willing to provide written informed consent -
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.